Embecta Investors File Class Action Following 57% Stock Plunge
A federal securities fraud lawsuit now targets Embecta Corp. and its senior leadership, alleging the medical device company misled shareholders regarding the market performance of its insulin pen portfolio. The litigation follows a catastrophic 57.8% single-day collapse in the company’s stock price recorded on May 5, 2026.
The complaint, filed in the U.S. District Court for the District of New Jersey under the caption Apitz-Grossman v. Embecta Corp., et al., claims executives repeatedly touted the resilience of the company’s insulin pen needles while failing to disclose significant competition and broader market softness. These statements, investors argue, masked a reality of declining volume that culminated in disappointing second-quarter results.
On May 5, 2026, the company admitted to share loss within its product category and a marked decline in retail channel demand. Embecta simultaneously slashed its quarterly dividend from $0.15 to $0.01 per share. The disclosure triggered a massive sell-off, driving the stock price from $9.25 to $3.90 in a single session. Bleichmar Fonti & Auld LLP, the firm representing the class, has set an August 17, 2026, deadline for shareholders to petition the court for lead plaintiff status.
Comments (0)
No comments yet. Be the first!